All News

EULAR19.abstract.jpg (keep)

Featured Abstracts from Industry at EULAR 2021

Jack Cush, MD

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
COVID.Flu_.Virus_.jpg (keep)

Factors Associated with COVID-19 Deaths in Rheumatic Patients

Jack Cush, MD

Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.

Read Article
RheumNow Podcast square

RheumNow Podcast – Myth Busters (5.21.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
Promising preclinical data of novel dual BAFF/APRIL inihibitor ALPN-303 re:efficacy & immunomodulatory activity vs TACI-i. Could deplete plasma cell compared to anti-CD20 mAbs in #SLE. Be interesting to see how it’ll fare in future clinical trials #EULAR2021 #OP0039 @RheumNow https://t.co/LnQzO67gwI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Eric Dein ejdein1 ( View Tweet)

Longitudinal UK SLE inception cohort 273 pts found: 👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate 👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx. 👉unexpected⬆️mortality in Caucasians 38% deaths IHD, 23% infx Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R
k dao KDAO2011 ( View Tweet)

Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP

k dao KDAO2011 ( View Tweet)
C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE! French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE
k dao KDAO2011 ( View Tweet)
Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX
k dao KDAO2011 ( View Tweet)
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao KDAO2011 ( View Tweet)
Plenary abstract #OP0013. In autoimmunity: Male lipoprotein profile: ^ CV risk, but had ^ anti-inflammatory features vs females, 2/2 sex hormones. Possible pathway to dx and tx of inflammatory disease in the future? #EULAR2021 @RheumNow @eular_org https://t.co/Z2KmEQftve

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj
k dao KDAO2011 ( View Tweet)
What is your treat to target for lupus patients? #EULAR2021 @rheumnow

k dao KDAO2011 ( View Tweet)

"50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU
k dao KDAO2011 ( View Tweet)
Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow 👉SLEDAI=0 👉MD global<0.5 👉dsDNA, C3/C4 does not matter 👉prednisone <=5 mg/d, stable meds 👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
k dao KDAO2011 ( View Tweet)
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/lmXBbJz6ts

Links:

Dr. John Cush RheumNow ( View Tweet)

Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Mike Putman - TULIP Trials - Anifrolumab in SLE https://t.co/cqZiulDMFm https://t.co/Vo17RfBOSk

Links:

Dr. John Cush RheumNow ( View Tweet)
Cohort analysis of 251 SLE patients with and without new-onset arrhythmia (taken from 2499 incident SLE Taiwan claims data). Plaquenil use showed no increased risk of arrhythmia (adj OR = 1.49; 0.98-2.25) or ventricular arrhythmia (adjOR =1.02). https://t.co/vkTi3X7hiM

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×